yahoo_financeOriginal article
Regeneron Says Pasatru Showed Sustained Benefit in OPTIMA Trial Extension for Genetic Disorder
Data ReadoutpositivePasatruPositive
AI Analysis
Summary
Regeneron announced that Pasatru demonstrated sustained benefit in the OPTIMA trial extension for a genetic disorder. The positive data supports the continued development of the therapy.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
sustained benefit demonstrated in OPTIMA trial extension
Importance:6/10
Sentiment:
0.70
clinical trialrare diseasegene therapypositive data
Related Companies
Read the original article
Published by yahoo_finance on October 12, 2026 5:16 PM